Citations (185)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (25)
Asef Azad, Ümmü Rana Gökmen, Hilmi Uysal, Sadi Köksoy, Uğur Bilge & Ayşe Esra Manguoğlu. (2023) Autophagy dysregulation plays a crucial role in regulatory T-cell loss and neuroinflammation in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-9.
Read now
Read now
Hee Jo Han, Ha Young Shin, Young-Chul Choi, Seung Min Kim & Seung Woo Kim. (2022) Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone. Redox Report 27:1, pages 79-84.
Read now
Read now
Hiroshi Mitsumoto, Diana C. Garofalo, Madison Gilmore, Leslie Andrews, Regina M. Santella, Howard Andrews, Martin McElhiney, Jennifer Murphy, Jeri W. Nieves, Judith Rabkin, Jonathan Hupf, D. Kevin Horton, Paul Mehta & Pam Factor-Litvak. (2022) Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23:3-4, pages 190-202.
Read now
Read now
R Hergesheimer, D Lanznaster, P Vourc’h, Cr Andres, Se Bakkouche, S Beltran, H Blasco, P Corcia & P Couratier. (2020) Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 21:9, pages 1103-1110.
Read now
Read now
Fufeng Liu, Zheng Ma, Jingcheng Sang & Fuping Lu. (2020) Edaravone inhibits the conformational transition of amyloid-β42: insights from molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics 38:8, pages 2377-2388.
Read now
Read now
Joseph M. Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda, Shawn Liu, Jeffrey Zhang & Wendy Agnese. (2019) Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:5-6, pages 421-431.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
Marion C. Hogg, Luise Halang, Ina Woods, Karen S. Coughlan & Jochen H. M. PREHN. (2018) Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:5-6, pages 438-445.
Read now
Read now
Alexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki, Alex Kim, Yannong Zhang, Takanori Saita & Masahiko Wasaki. (2017) A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 71-79.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 88-97.
Read now
Read now
Koji Takei, Kazutoshi Watanabe, Satoshi Yuki, Makoto Akimoto, Takeshi Sakata & Joseph Palumbo. (2017) Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 5-10.
Read now
Read now
Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, Koji Takei, Joseph Palumbo & Masayuki Suzuki. (2017) Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 80-87.
Read now
Read now
Hideyuki Sawada. (2017) Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 18:7, pages 735-738.
Read now
Read now
Ankit Parikh, Krishna Kathawala, Chun Chuan Tan, Sanjay Garg & Xin-Fu Zhou. (2017) Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. Drug Delivery 24:1, pages 962-978.
Read now
Read now
H Blasco, F Patin, CR Andres, P Corcia & PH Gordon. (2016) Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy 17:12, pages 1669-1682.
Read now
Read now
Akio Fujisawa & Yorihiro Yamamoto. (2016) Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Report 21:3, pages 98-103.
Read now
Read now
Yanxin Ren, Bing Wei, Xirui Song, Nan An, Yiying Zhou, Xinxin Jin & Yuyang Zhang. (2015) Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature. International Journal of Neuroscience 125:8, pages 555-565.
Read now
Read now
Koji Abe, Yasuto Itoyama, Gen Sobue, Shoji Tsuji, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Kazuoki Kondo, Takatomo Yoneoka, Makoto Akimoto & Hiide Yoshino. (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:7-8, pages 610-617.
Read now
Read now
Ali Aamer Habib & Hiroshi Mitsumoto. (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opinion on Emerging Drugs 16:3, pages 537-558.
Read now
Read now
Stefano Zoccolella, Andrea Santamato & Paolo Lamberti. (2009) Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment 5, pages 577-595.
Read now
Read now
Yukihito Higashi. (2009) Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opinion on Pharmacotherapy 10:2, pages 323-331.
Read now
Read now
Masahiko Yamamoto, Fumiaki Tanaka, Hiroshi Tatsumi & Gen Sobue. (2008) A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies. Expert Opinion on Pharmacotherapy 9:11, pages 1845-1857.
Read now
Read now
Hiroshi Mitsumoto, Regina M. Santella, Xinhua Liu, Mikhail Bogdanov, Jennifer Zipprich, Hui-Chen Wu, Julie Mahata, Mary Kilty, Kate Bednarz, Daniel Bell, Paul H. Gordon, Mady Hornig, Mahsa Mehrazin, Ali Naini, M. Flint Beal & Pam Factor-Litvak. (2008) Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis 9:3, pages 177-183.
Read now
Read now
Richard S Bedlack$suffix/text()$suffix/text(), Bryan J Traynor$suffix/text()$suffix/text() & Merit E Cudkowicz$suffix/text()$suffix/text(). (2007) Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opinion on Emerging Drugs 12:2, pages 229-252.
Read now
Read now
Articles from other publishers (160)
Soju Seki, Yoshihiro Kitaoka, Sou Kawata, Akira Nishiura, Toshihiro Uchihashi, Shin-ichiro Hiraoka, Yusuke Yokota, Emiko Tanaka Isomura, Mikihiko Kogo & Susumu Tanaka. (2023) Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy. Biomedicines 11:11, pages 2967.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Crossref
Ambereen K. Mehta, Max Sarmet, Samuel Maiser, Jenny A. Meyer, Sherry Kolodziejczak, Karla Washington & Zachary Simmons. (2023)
Quality‐of‐life assessment instruments used across
ALS
clinics
. Muscle & Nerve 68:6, pages 865-872.
Crossref
Crossref
Nicholas J. Maragakis, Mamede de Carvalho & Michael D. Weiss. (2023)
Therapeutic targeting of
ALS
pathways: Refocusing an incomplete picture
. Annals of Clinical and Translational Neurology 10:11, pages 1948-1971.
Crossref
Crossref
Christina Martin Schaff, Jerome E. Kurent, Sherry Kolodziejczak, Michelle Milic, Laura A. Foster & Ambereen K. Mehta. (2023) Neuroprognostication for Patients with Amyotrophic Lateral Sclerosis: An Updated, Evidence-Based Review. Seminars in Neurology 43:05, pages 776-790.
Crossref
Crossref
Anas Zakarya Nourelden, Ibrahim Kamal, Abdulrahman Ibrahim Hagrass, Abdelrahman G. Tawfik, Mahmoud M. Elhady, Ahmed Hashem Fathallah, Mona Muhe Eldeen Eshag & Mohamed Sayed Zaazouee. (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences 44:10, pages 3429-3442.
Crossref
Crossref
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt & Meret Herdick. (2023) Current State and Future Directions in the Therapy of ALS. Cells 12:11, pages 1523.
Crossref
Crossref
Arsh Haj Mohamad Ebrahim Ketabforoush, Rojin Chegini, Shirin Barati, Fatemeh Tahmasebi, Bardia Moghisseh, Mohammad Taghi Joghataei, Faezeh Faghihi & Fereshteh Azedi. (2023) Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomedicine & Pharmacotherapy 160, pages 114378.
Crossref
Crossref
Mukesh Gautam, Barış Genç, Benjamin Helmold, Angela Ahrens, Janis Kuka, Marina Makrecka-Kuka, Aksu Günay, Nuran Koçak, Izaak R. Aguilar-Wickings, Dennis Keefe, Guozhu Zheng, Suchitra Swaminathan, Martin Redmon, Hatim A. Zariwala & P. Hande Özdinler. (2023) SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function. Neurobiology of Disease 178, pages 106022.
Crossref
Crossref
Edward O. Olufunmilayo, Michelle B. Gerke-Duncan & R. M. Damian Holsinger. (2023) Oxidative Stress and Antioxidants in Neurodegenerative Disorders. Antioxidants 12:2, pages 517.
Crossref
Crossref
Zeynep YILDIRIM, Dicle Naz TOKTAŞ, Öznur DEMİR, Zülfiye GÜL & Burcu ŞEN UTSUKARÇİ. (2023) Amyotrofik Lateral Skleroz Patofizyolojisi ve Tedavi YaklaşımlarıAn Evaluation of Amyotrophic Lateral Sclerosis and Current Situation in Its Treatment. Hacettepe University Journal of the Faculty of Pharmacy.
Crossref
Crossref
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin & Carlayne E. Jackson. (2022) Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle & Nerve 67:2, pages 124-129.
Crossref
Crossref
Shotaro Haji, Koji Fujita, Ryosuke Oki, Yusuke Osaki, Ryosuke Miyamoto, Hiroyuki Morino, Seiichi Nagano, Naoki Atsuta, Yuki Kanazawa, Yuki Matsumoto, Atsuko Arisawa, Hisashi Kawai, Yasutaka Sato, Satoshi Sakaguchi, Kenta Yagi, Tatsuto Hamatani, Tatsuo Kagimura, Hiroaki Yanagawa, Hideki Mochizuki, Manabu Doyu, Gen Sobue, Masafumi Harada & Yuishin Izumi. (2023) An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study. JMIR Research Protocols 12, pages e42032.
Crossref
Crossref
Jan Lejman, Kinga Panuciak, Emilia Nowicka, Angelika Mastalerczyk, Katarzyna Wojciechowska & Monika Lejman. (2023) Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. International Journal of Molecular Sciences 24:2, pages 1130.
Crossref
Crossref
Daisuke Ito, Satoru Morimoto, Shinichi Takahashi, Kensuke Okada, Jin Nakahara & Hideyuki Okano. (2023) Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain 146:1, pages 13-19.
Crossref
Crossref
Mengxia Gao, Lingqun Zhu, Jingling Chang, Tianyu Cao, Lianying Song, Chunli Wen, Yi Chen, Yudi Zhuo & Fei Chen. (2022) Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clinical Drug Investigation 43:1, pages 1-11.
Crossref
Crossref
Cinzia Volonté, Justin J. Yerbury & Ronald Sluyter. 2023. Purinergic Signaling in Neurodevelopment, Neuroinflammation and Neurodegeneration. Purinergic Signaling in Neurodevelopment, Neuroinflammation and Neurodegeneration
223
258
.
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Masaki Ueda, Shoko Yokota, Yuichiro Kato & Manabu Hirai. (2022) Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Clinical Pharmacology in Drug Development 12:1, pages 77-84.
Crossref
Crossref
Paula Sienes Bailo, Elena Llorente Martín, Pilar Calmarza, Silvia Montolio Breva, Adrián Bravo Gómez, Adela Pozo Giráldez, Joan J. Sánchez-Pascuala Callau, Juana M. Vaquer Santamaría, Anita Dayaldasani Khialani, Concepción Cerdá Micó, Jordi Camps Andreu, Guillermo Sáez Tormo & Isabel Fort Gallifa. (2022) The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 3:4, pages 342-350.
Crossref
Crossref
Paula Sienes Bailo, Elena Llorente Martín, Pilar Calmarza, Silvia Montolio Breva, Adrián Bravo Gómez, Adela Pozo Giráldez, Joan José Sánchez-Pascuala Callau, Juana Maria Vaquer Santamaría, Anita Dayaldasani Khialani, Concepción Cerdá Micó, Jordi Camps Andreu, Guillermo Sáez Tormo & Isabel Fort Gallifa. (2022) Implicación del estrés oxidativo en las enfermedades neurodegenerativas y posibles terapias antioxidantes. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 3:4, pages 351-360.
Crossref
Crossref
Stephen A Goutman, Kai Guo, Masha G Savelieff, Adam Patterson, Stacey A Sakowski, Hani Habra, Alla Karnovsky, Junguk Hur & Eva L Feldman. (2022) Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain 145:12, pages 4425-4439.
Crossref
Crossref
Oscar Bate Akide Ndunge, Nicole Kilian & Mootaz M. Salman. (2022)
Cerebral Malaria and Neuronal Implications of
Plasmodium Falciparum
Infection: From Mechanisms to Advanced Models
. Advanced Science 9:36.
Crossref
Crossref
Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson & Yoshiteru Ushirogawa. (2022)
Associations between the
ALSFRS‐R
score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of
ALSFRS‐R
scores in clinical studies
MCI186
‐16,
MCI186
‐17, and
MCI186
‐19
. Muscle & Nerve 66:5, pages 593-602.
Crossref
Crossref
Qian Li, Yizhi Zhang, Jinglu Hu, Bochuan Yuan, Pengcheng Zhang, Yaxin Wang, Xu Jin, Lina Du & Yiguang Jin. (2022) The Improved Brain-Targeted Drug Delivery of Edaravone Temperature-Sensitive Gels by Ultrasound for γ-ray Radiation-Induced Brain Injury. Pharmaceutics 14:11, pages 2281.
Crossref
Crossref
Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama & Hiroyoshi Kakuyama. (2022) Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI‐589 in Healthy Participants. Clinical Pharmacology in Drug Development 11:10, pages 1136-1146.
Crossref
Crossref
José Jiménez-Villegas, Janine Kirby, Ana Mata, Susana Cadenas, Martin R. Turner, Andrea Malaspina, Pamela J. Shaw, Antonio Cuadrado & Ana I. Rojo. (2022) Dipeptide Repeat Pathology in C9orf72-ALS Is Associated with Redox, Mitochondrial and NRF2 Pathway Imbalance. Antioxidants 11:10, pages 1897.
Crossref
Crossref
Teresa Cunha‐Oliveira, Daniela Franco Silva, Luis Segura, Inês Baldeiras, Ricardo Marques, Tatiana Rosenstock, Paulo J. Oliveira & Filomena S. G. Silva. (2022) Redox profiles of amyotrophic lateral sclerosis lymphoblasts with or without known SOD1 mutations. European Journal of Clinical Investigation 52:9.
Crossref
Crossref
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, Dylan Neel, Donatienne Van Weehaeghe, James D. Berry & Sabrina Paganoni. (2022) Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs 82:13, pages 1367-1388.
Crossref
Crossref
Leenor Alfahel, Shirel Argueti-Ostrovsky, Shir Barel, Mahmood Ali Saleh, Joy Kahn, Salome Azoulay-Ginsburg, Ayelet Rothstein, Simon Ebbinghaus, Arie Gruzman & Adrian Israelson. (2022) 4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice. International Journal of Molecular Sciences 23:16, pages 9403.
Crossref
Crossref
Andrew T. Nelson & Davide Trotti. (2022) Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis. Neurotherapeutics 19:4, pages 1102-1118.
Crossref
Crossref
Jiantao Zhao, Xuemei Wang, Zijun Huo, Yanchun Chen, Jinmeng Liu, Zhenhan Zhao, Fandi Meng, Qi Su, Weiwei Bao, Lingyun Zhang, Shuang Wen, Xin Wang, Huancai Liu & Shuanhu Zhou. (2022) The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis. Cells 11:13, pages 2049.
Crossref
Crossref
Frank W. Pun, Bonnie Hei Man Liu, Xi Long, Hoi Wing Leung, Geoffrey Ho Duen Leung, Quinlan T. Mewborne, Junli Gao, Anastasia Shneyderman, Ivan V. Ozerov, Ju Wang, Feng Ren, Alexander Aliper, Evelyne Bischof, Evgeny Izumchenko, Xiaoming Guan, Ke Zhang, Bai Lu, Jeffrey D. Rothstein, Merit E. Cudkowicz & Alex Zhavoronkov. (2022) Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Subhavi De Silva, Bradley J. Turner & Nirma D. Perera. (2022) Metabolic Dysfunction in Motor Neuron Disease: Shedding Light through the Lens of Autophagy. Metabolites 12:7, pages 574.
Crossref
Crossref
Shlomit Ezer, Muhannad Daana, Julien H Park, Shira Yanovsky-Dagan, Ulrika Nordström, Adily Basal, Simon Edvardson, Ann Saada, Markus Otto, Vardiella Meiner, Stefan L Marklund, Peter Munch Andersen & Tamar Harel. (2022)
Infantile SOD1 deficiency syndrome caused by a homozygous
SOD1
variant with absence of enzyme activity
. Brain 145:3, pages 872-878.
Crossref
Crossref
Myrsini Chamakioti, Nikolaos Karantzelis & Stavros Taraviras. (2022) Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies. International Journal of Molecular Sciences 23:9, pages 4824.
Crossref
Crossref
Barış Genç, Mukesh Gautam, Benjamin R. Helmold, Nuran Koçak, Aksu Günay, Gashaw M. Goshu, Richard B. Silverman & P. Hande Ozdinler. (2022) NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone. Scientific Reports 12:1.
Crossref
Crossref
Belgin Sever, Halilibrahim Ciftci, Hasan DeMirci, Hilal Sever, Firdevs Ocak, Burak Yulug, Hiroshi Tateishi, Takahisa Tateishi, Masami Otsuka, Mikako Fujita & Ayşe Nazlı Başak. (2022) Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:5, pages 2400.
Crossref
Crossref
Hideyuki Okano & Satoru Morimoto. (2022) iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell 29:2, pages 189-208.
Crossref
Crossref
Simon Witzel, André Maier, Robert Steinbach, Julian Grosskreutz, Jan C. Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer & Albert C. Ludolph. (2022) Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology 79:2, pages 121.
Crossref
Crossref
Sun Joo Cha & Kiyoung Kim. (2022) Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection. Antioxidants 11:2, pages 195.
Crossref
Crossref
Ryan M. Williams, Janki Shah, Elizabeth Mercer, Helen S. Tian, Vanessa Thompson, Justin M. Cheung, Madeline Dorso, Jaclyn M. Kubala, Lorraine J. Gudas, Elisa de Stanchina, Edgar A. Jaimes & Daniel A. Heller. (2022) Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury. Frontiers in Pharmacology 12.
Crossref
Crossref
Pedro Henrique Villar-Delfino, Nathália Augusta Oliveira Gomes, Paulo Pereira Christo, José Augusto Nogueira-Machado & Caroline Maria Oliveira Volpe. (2022) Edaravone Inhibits the Production of Reactive Oxygen Species in Phagocytosis- and PKC-Stimulated Granulocytes from Multiple Sclerosis Patients Edaravone Modulate Oxidative Stress in Multiple Sclerosis. Journal of Central Nervous System Disease 14, pages 117957352210925.
Crossref
Crossref
Magisetty Obulesu. 2022. Plant Extracts in Neurodegenerative Diseases. Plant Extracts in Neurodegenerative Diseases
101
115
.
Pasha Apontes. 2022. TDP-43 and Neurodegeneration. TDP-43 and Neurodegeneration
183
250
.
Anju Singh, Ritushree Kukreti & Shrikant Kukreti. 2022. Neurodegenerative Diseases Biomarkers. Neurodegenerative Diseases Biomarkers
121
154
.
Sweta Shah, Marc Marie Dooms, Sofia Amaral-Garcia & Mariana Igoillo-Esteve. (2021) Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Tesfaye Wolde Tefera, Frederik J. Steyn, Shyuan T. Ngo & Karin Borges. (2021) CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?. Cell & Bioscience 11:1.
Crossref
Crossref
Zaynab Shakkour, Karl John Habashy, Moussa Berro, Samira Takkoush, Samar Abdelhady, Nadia Koleilat, Ali H. Eid, Kazem Zibara, Makram Obeid, Deborah Shear, Stefania Mondello, Kevin K. Wang & Firas Kobeissy. (2020) Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. The Neuroscientist 27:6, pages 620-649.
Crossref
Crossref
Defne A. Amado & Beverly L. Davidson. (2021) Gene therapy for ALS: A review. Molecular Therapy 29:12, pages 3345-3358.
Crossref
Crossref
Ismail Ibrahim Ismail, Fathi Massoud, Walaa Ahmed Kamel & Jasem Youssef Al-Hashel. (2020) Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience. Acta Neurologica Belgica 121:6, pages 1591-1597.
Crossref
Crossref
C. Quarracino, M. Bendersky, R. Rey & G. E. Rodríguez. (2020) Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina. Acta Neurologica Belgica 121:6, pages 1519-1523.
Crossref
Crossref
Sun Hwa Lee, Mudan Cai & Eun Jin Yang. (2021) Anti-inflammatory Effects of a Novel Herbal Extract in the Muscle and Spinal Cord of an Amyotrophic Lateral Sclerosis Animal Model. Frontiers in Neuroscience 15.
Crossref
Crossref
Fréderike W. Riemslagh, Rob F. M. Verhagen, Esmay C. van der Toorn, Daphne J. Smits, Wim H. Quint, Herma C. van der Linde, Tjakko J. van Ham & Rob Willemsen. (2021) Reduction of oxidative stress suppresses poly-GR-mediated toxicity in zebrafish embryos. Disease Models & Mechanisms 14:11.
Crossref
Crossref
Takashi Hosaka, Hiroshi Tsuji & Akira Tamaoka. (2021) Biomolecular Modifications Linked to Oxidative Stress in Amyotrophic Lateral Sclerosis: Determining Promising Biomarkers Related to Oxidative Stress. Processes 9:9, pages 1667.
Crossref
Crossref
J. Jiménez-Villegas, L. Ferraiuolo, R.J. Mead, P.J. Shaw, A. Cuadrado & A.I. Rojo. (2021) NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radical Biology and Medicine 173, pages 125-141.
Crossref
Crossref
Maximillian Taro William Lee, William Mahy & Mark David Rackham. (2021) The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. RSC Medicinal Chemistry 12:8, pages 1281-1311.
Crossref
Crossref
Xiaojiao Xu, Dingding Shen, Yining Gao, Qinming Zhou, You Ni, Huanyu Meng, Hongqin Shi, Weidong Le, Shengdi Chen & Sheng Chen. (2021) A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?. Translational Neurodegeneration 10:1.
Crossref
Crossref
James BerryBenjamin Brooks, Angela GengeTerry Heiman-PattersonStanley AppelMichael BenatarRobert BowserMerit CudkowiczClifton GoochJeremy ShefnerJurjen WestraWendy AgneseCharlotte MerrillSally NelsonStephen Apple. (2021) Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS). Neurology Clinical Practice 11:4.
Crossref
Crossref
Jannigje Rachel Kok, Nelma M. Palminha, Cleide Dos Santos Souza, Sherif F. El-Khamisy & Laura Ferraiuolo. (2021) DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cellular and Molecular Life Sciences 78:15, pages 5707-5729.
Crossref
Crossref
Stephanie R Shepheard, Matthew D Parker, Johnathan Cooper-Knock, Nick S Verber, Lee Tuddenham, Paul Heath, Nick Beauchamp, Elsie Place, Elizabeth S A Sollars, Martin R Turner, Andrea Malaspina, Pietro Fratta, Channa Hewamadduma, Thomas M Jenkins, Christopher J McDermott, Dennis Wang, Janine Kirby & Pamela J Shaw. (2021) Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 92:5, pages 510-518.
Crossref
Crossref
Hyungsun Park, Jongyoon Kim, Chihoon Shin & Seongju Lee. (2021) Intersection between Redox Homeostasis and Autophagy: Valuable Insights into Neurodegeneration. Antioxidants 10:5, pages 694.
Crossref
Crossref
Zaynab Shakkour, Hawraa Issa, Helene Ismail, Ohanes Ashekyan, Karl John Habashy, Leila Nasrallah, Hussam Jourdi, Eva Hamade, Stefania Mondello, Mirna Sabra, Kazem Zibara & Firas Kobeissy. (2021) Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry 28:12, pages 2369-2391.
Crossref
Crossref
Chaohua Cong, Weiwei Liang, Chunting Zhang, Ying Wang, Yueqing Yang, Xudong Wang, Shuyu Wang, Di Huo, Hongyong Wang, Di Wang & Honglin Feng. (2021)
PAK4 suppresses motor neuron degeneration in hSOD1
G93A
‐linked amyotrophic lateral sclerosis cell and rat models
. Cell Proliferation 54:4.
Crossref
Crossref
Ülkü Mete Ural, Beril Gürlek & Ahmet Alver. (2020) Protective effect of edaravone against radiation-induced ovarian injury: a histopathological and immunohistochemical evaluation in an experimental rat model. Archives of Gynecology and Obstetrics 303:4, pages 1009-1016.
Crossref
Crossref
Elisabeth Traiffort, Séverine Morisset-Lopez, Mireille Moussaed & Amina Zahaf. (2021) Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 22:7, pages 3426.
Crossref
Crossref
Xiao-Le Wang, Si-Tong Feng, Zhen-Zhen Wang, Nai-Hong Chen & Yi Zhang. (2021) Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases. Pharmacological Research 165, pages 105433.
Crossref
Crossref
Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana Sanchez, Gashaw M. Goshu, Nuran Koçak, Edward Xie, Richard B. Silverman & P. Hande Özdinler. (2021) Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology. Clinical and Translational Medicine 11:2.
Crossref
Crossref
Asako Kakimoto, Masatoshi Ishizaki, Hidetsugu Ueyama, Yasushi Maeda & Mitsuharu Ueda. (2021) Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone. Medicine 100:21, pages e26127.
Crossref
Crossref
Nikita Sharma, R. Mankamna Kumari, Geeta Arya, Nidhi Gupta, Ramesh Chandra & Surendra Nimesh. 2021. Clinical Perspectives and Targeted Therapies in Apoptosis. Clinical Perspectives and Targeted Therapies in Apoptosis
329
391
.
Stephen A Goutman, Jonathan Boss, Kai Guo, Fadhl M Alakwaa, Adam Patterson, Sehee Kim, Masha Georges Savelieff, Junguk Hur & Eva L Feldman. (2020) Untargeted metabolomics yields insight into ALS disease mechanisms. Journal of Neurology, Neurosurgery & Psychiatry 91:12, pages 1329-1338.
Crossref
Crossref
Jessica A. Cooksey & Amen Sergew. (2020) Noninvasive Ventilation in Amyotrophic Lateral Sclerosis. Sleep Medicine Clinics 15:4, pages 527-538.
Crossref
Crossref
Teresa Cunha-Oliveira, Liliana Montezinho, Catarina Mendes, Omidreza Firuzi, Luciano Saso, Paulo J. Oliveira & Filomena S. G. Silva. (2020) Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxidative Medicine and Cellular Longevity 2020, pages 1-29.
Crossref
Crossref
Luke McAlary, Yee Lian Chew, Jeremy Stephen Lum, Nicholas John Geraghty, Justin John Yerbury & Neil R. Cashman. (2020) Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises. Frontiers in Cellular Neuroscience 14.
Crossref
Crossref
Juan Fernando Ortiz, Sawleha Arshi Khan, Amr Salem, Zayar Lin, Zafar Iqbal & Nusrat Jahan. (2020) Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus.
Crossref
Crossref
Helene Ismail, Zaynab Shakkour, Maha Tabet, Samar Abdelhady, Abir Kobaisi, Reem Abedi, Leila Nasrallah, Gianfranco Pintus, Yusra Al-Dhaheri, Stefania Mondello, Riyad El-Khoury, Ali H. Eid, Firas Kobeissy & Johnny Salameh. (2020) Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone. Antioxidants 9:10, pages 943.
Crossref
Crossref
Satoshi Yuki, Kaoru Ishizaki, Hanami Yoshioka, Hidekazu Nakamura, Manabu Hirai & Gen Sobue. (2020) Baseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan). Neurology and Clinical Neuroscience 8:5, pages 261-269.
Crossref
Crossref
Peter Karagiannis & Haruhisa Inoue. (2020) ALS, a cellular whodunit on motor neuron degeneration. Molecular and Cellular Neuroscience 107, pages 103524.
Crossref
Crossref
Baskaran Stephen Inbaraj & Bing-Huei Chen. (2020) An overview on recent in vivo biological application of cerium oxide nanoparticles. Asian Journal of Pharmaceutical Sciences 15:5, pages 558-575.
Crossref
Crossref
Yasuyuki Ohta, Toru Yamashita, Emi Nomura, Nozomi Hishikawa, Ken Ikegami, Yosuke Osakada, Namiko Matsumoto, Yuko Kawahara, Taijun Yunoki, Yoshiaki Takahashi, Motonori Takamiya, Koh Tadokoro, Ryo Sasaki, Yumiko Nakano, Keiichiro Tsunoda, Kota Sato, Yoshio Omote, Mami Takemoto & Koji Abe. (2020) Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. Journal of the Neurological Sciences 415, pages 116906.
Crossref
Crossref
J. P. J. M. de Munter, J. Mey, T. Strekalova, B. W. Kramer & E. Ch. Wolters. (2020) Why do anti-inflammatory signals of bone marrow-derived stromal cells improve neurodegenerative conditions where anti-inflammatory drugs fail?. Journal of Neural Transmission 127:5, pages 715-727.
Crossref
Crossref
Cristina Agresti, Rosella Mechelli, Stefania Olla, Caterina Veroni, Cecilia Eleuteri, Giovanni Ristori & Marco Salvetti. (2020) Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone. Current Medicinal Chemistry 27:13, pages 2095-2105.
Crossref
Crossref
Honglin Tan, Mina Chen, Dejiang Pang, Xiaoqiang Xia, Chongyangzi Du, Wanchun Yang, Yiyuan Cui, Chao Huang, Wanxiang Jiang, Dandan Bi, Chunyu Li, Huifang Shang, Paul F. Worley & Bo Xiao. (2019) LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice. Cell Death & Differentiation 27:4, pages 1369-1382.
Crossref
Crossref
Ekta Singh & Giles Devasahayam. (2020) Neurodegeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection. Molecular Biology Reports 47:4, pages 3133-3140.
Crossref
Crossref
Sandra Carrera-Juliá, Mari Luz Moreno, Carlos Barrios, Jose Enrique de la Rubia Ortí & Eraci Drehmer. (2020) Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review. Frontiers in Physiology 11.
Crossref
Crossref
Veronica Laos, Dezmond Bishop, Christian A. Lang, Nicole M. Marsh, Kristi Lazar Cantrell, Steven K. Buratto, Ambuj K. Singh & Michael T. Bowers. (2019)
Modulating ALS-Related Amyloidogenic TDP-43
307–319
Oligomeric Aggregates with Computationally Derived Therapeutic Molecules
. Biochemistry 59:4, pages 499-508.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
E. I. Ustyantseva, S. P. Medvedev & S. M. Zakian. 2020. Mechanisms of Genome Protection and Repair. Mechanisms of Genome Protection and Repair
195
217
.
Kyle J. Trageser, Chad Smith, Francis J. Herman, Kenjiro Ono & Giulio Maria Pasinetti. (2019) Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience 13.
Crossref
Crossref
Satoru Morimoto, Shinichi Takahashi, Komei Fukushima, Hideyuki Saya, Norihiro Suzuki, Masashi Aoki, Hideyuki Okano & Jin Nakahara. (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis – Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regenerative Therapy 11, pages 143-166.
Crossref
Crossref
Ana Estevez, Mallikarjunarao Ganesana, John Trentini, James Olson, Guangze Li, Yvonne Boateng, Jennifer Lipps, Sarah Yablonski, William Donnelly, James Leiter & Joseph Erlichman. (2019) Antioxidant Enzyme-Mimetic Activity and Neuroprotective Effects of Cerium Oxide Nanoparticles Stabilized with Various Ratios of Citric Acid and EDTA. Biomolecules 9:10, pages 562.
Crossref
Crossref
Hirokazu Yokoyama, Masaya Tsujii, Takahiro Iino, Tomoki Nakamura & Akihiro Sudo. (2019) Inhibitory effect of edaravone on systemic inflammation and local damage in skeletal muscles following long-term ischemia to murine hind limb. Journal of Orthopaedic Surgery 27:3, pages 230949901987447.
Crossref
Crossref
Emma F. Smith, Pamela J. Shaw & Kurt J. De Vos. (2019) The role of mitochondria in amyotrophic lateral sclerosis. Neuroscience Letters 710, pages 132933.
Crossref
Crossref
Andrea Fortuna, Matteo Gizzi, Luca Bello, Ilaria Martinelli, Cinzia Bertolin, Elena Pegoraro, Maurizio Corbetta & Gianni Sorarù. (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. Journal of the Neurological Sciences 404, pages 47-51.
Crossref
Crossref
Gessica Sala, Alessandro Arosio, Elisa Conti, Simone Beretta, Christian Lunetta, Nilo Riva, Carlo Ferrarese & Lucio Tremolizzo. (2019) Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes. Clinical Psychopharmacology and Neuroscience 17:3, pages 438-442.
Crossref
Crossref
Audrey M. G. Ragagnin, Sina Shadfar, Marta Vidal, Md Shafi Jamali & Julie D. Atkin. (2019) Motor Neuron Susceptibility in ALS/FTD. Frontiers in Neuroscience 13.
Crossref
Crossref
Zeynep Ünlütürk & Çağdaş Erdoğan. (2019) Amiyotrofik Lateral Skleroz Tedavisinde Güncel Onaylanmış Hastalık Modifiye Edici Tedavi: Riluzol ve Edaravone. Pamukkale Medical Journal.
Crossref
Crossref
Yasuyuki Ohta, Emi Nomura, Jingwei Shang, Tian Feng, Yong Huang, Xia Liu, Xiaowen Shi, Yumiko Nakano, Nozomi Hishikawa, Kota Sato, Mami Takemoto, Toru Yamashita & Koji Abe. (2018) Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. Journal of Neuroscience Research 97:5, pages 607-619.
Crossref
Crossref
Anju Singh, Ritushree Kukreti, Luciano Saso & Shrikant Kukreti. (2019) Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 24:8, pages 1583.
Crossref
Crossref
Archana Prasad, Vidhya Bharathi, Vishwanath Sivalingam, Amandeep Girdhar & Basant K. Patel. (2019) Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience 12.
Crossref
Crossref
Linting Luo, Zhibin Song, Xiaoqiang Li, Huiwang, Yaqing Zeng, Qinwang, Meiqi & Jianli He. (2018) Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis. Neurological Sciences 40:2, pages 235-241.
Crossref
Crossref
Stephen Morgan, Stephanie Duguez & William Duddy. (2018) Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge. Journal of Personalized Medicine 8:4, pages 44.
Crossref
Crossref
Teodorico C. Ramalho, Alexandre A. de Castro, Tássia S. Tavares, Maria C. Silva, Daniela R. Silva, Pedro H. Cesar, Lucas A. Santos, Elaine F.F. da Cunha, Eugenie Nepovimova & Kamil Kuca. (2018) Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations. Progress in Neurobiology 169, pages 135-157.
Crossref
Crossref
Sungwoo Hyung, Yoo-Seong Jeong, Jungmin Yeo, Yoo-Kyung Song, Min-Soo Kim, Young-Jae Im, Han-Joo Maeng & Suk-Jae Chung. (2018) Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. European Journal of Pharmaceutical Sciences 123, pages 312-320.
Crossref
Crossref
Jui-Hao Lee, Jen-Wei Liu, Shinn-Zong Lin, Horng-Jyh Harn & Tzyy-Wen Chiou. (2018) Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis. Cell Transplantation 27:9, pages 1301-1312.
Crossref
Crossref
Osama A. Khairoalsindi & Ahmad R. Abuzinadah. (2018) Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives. Neurology Research International 2018, pages 1-12.
Crossref
Crossref
Naoki Atsuta, Atsushi Hashizume, Gen Sobue & Masahisa Katsuno. (2018) IV. Motor neuron diseasesIV．運動ニューロン疾患. Nihon Naika Gakkai Zasshi 107:8, pages 1477-1485.
Crossref
Crossref
Naomi Tsuburaya, Kengo Homma, Tsunehiko Higuchi, Andrii Balia, Hiroyuki Yamakoshi, Norio Shibata, Seiichi Nakamura, Hidehiko Nakagawa, Shin-ichi Ikeda, Naoki Umezawa, Nobuki Kato, Satoshi Yokoshima, Masatoshi Shibuya, Manabu Shimonishi, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano, Isao Naguro, Keiko Imamura, Haruhisa Inoue, Takao Fujisawa & Hidenori Ichijo. (2018) A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Nature Communications 9:1.
Crossref
Crossref
Nadia D'AmbrosiMauro CozzolinoMaria Teresa Carrì. (2018) Neuroinflammation in Amyotrophic Lateral Sclerosis: Role of Redox (dys)Regulation. Antioxidants & Redox Signaling 29:1, pages 15-36.
Crossref
Crossref
Masamitsu Okada, Satoshi Yamashita, Hidetsugu Ueyama, Masatoshi Ishizaki, Yasushi Maeda & Yukio Ando. (2018) Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci 11, pages 11-14.
Crossref
Crossref
N.A. Nemytova, E.V. Shchegol’kov, Ya.V. Burgart, P.A. Slepukhin, S.S. Borisevich, S.L. Khursan & V.I. Saloutin. (2018) Regiocontrolled N-, O- and C-methylation of 1-phenyl-3-polyfluoroalkyl-1H-pyrazol-5-ols. Journal of Fluorine Chemistry 206, pages 72-81.
Crossref
Crossref
Hiroshi MitsumotoToyokazu Saito. (2018) A prognostic biomarker in amyotrophic lateral sclerosis筋萎縮性側索硬化症の進行を示すバイオマーカー. Rinsho Shinkeigaku 58:12, pages 729-736.
Crossref
Crossref
Kazutoshi Watanabe, Masahiko Tanaka, Satoshi Yuki, Manabu Hirai & Yorihiro Yamamoto. (2018) How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?. Journal of Clinical Biochemistry and Nutrition 62:1, pages 20-38.
Crossref
Crossref
Said R Beydoun & Jeffrey Rosenfeld. (2018) Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design. US Neurology 14:1, pages 47.
Crossref
Crossref
Andrew P. Tosolini & James N. Sleigh. (2017) Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Merry W. Ma, Jing Wang, Quanguang Zhang, Ruimin Wang, Krishnan M. Dhandapani, Ratna K. Vadlamudi & Darrell W. Brann. (2017) NADPH oxidase in brain injury and neurodegenerative disorders. Molecular Neurodegeneration 12:1.
Crossref
Crossref
Loqman A. Mohamed, Shashirekha Markandaiah, Silvia Bonanno, Piera Pasinelli & Davide Trotti. (2017) Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. The AAPS Journal 19:6, pages 1600-1614.
Crossref
Crossref
Shiori Ando, Michinori Funato, Kazuki Ohuchi, Tsubasa Kameyama, Satoshi Inagaki, Junko Seki, Chizuru Kawase, Kazuhiro Tsuruma, Masamitsu Shimazawa, Hideo Kaneko & Hideaki Hara. (2017) Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model. European Journal of Pharmacology 814, pages 161-168.
Crossref
Crossref
Nandini Ramesh & Udai Bhan Pandey. (2017) Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Kei Akaiwa, Kazuhiko Namekata, Yuriko Azuchi, Xiaoli Guo, Atsuko Kimura, Chikako Harada, Yoshinori Mitamura & Takayuki Harada. (2017) Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Cell Death & Disease 8:7, pages e2934-e2934.
Crossref
Crossref
Orla Hardiman & Leonard H van den Berg. (2017) Edaravone: a new treatment for ALS on the horizon?. The Lancet Neurology 16:7, pages 490-491.
Crossref
Crossref
Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino, Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Hidenao Sasaki, Ichiro Yabe, Shizuki Doi, Hitoshi Warita, Takashi Imai, Hiroaki Ito, Mitsumasa Fukuchi, Etsuko Osumi, Manabu Wada, Imaharu Nakano, Mitsuya Morita, Katsuhisa Ogata, Yuichi Maruki, Kimiko Ito, Osamu Kano, Mineo Yamazaki, Yuji Takahashi, Hiroyuki Ishiura, Mieko Ogino, Ryoko Koike, Chiho Ishida, Tsuyoshi Uchiyama, Kouichi Mizoguchi, Tomokazu Obi, Hirohisa Watanabe, Naoki Atsuta, Ikuko Aiba, Akira Taniguchi, Hideyuki Sawada, Takanori Hazama, Harutoshi Fujimura, Hirofumi Kusaka, Takenobu Kunieda, Hitoshi Kikuchi, Hidenori Matsuo, Hidetsugu Ueyama, Kazutoshi Uekawa, Masahiko Tanaka, Makoto Akimoto, Masaki Ueda, Aiko Murakami, Rie Sumii, Takuya Kudou, Kazue Nakamura, Kazunori Morimoto, Takatomo Yoneoka, Manabu Hirai, Kouichi Sasaki, Hidetomo Terai, Tomoko Natori, Hiroshi Matsui, Kuniko Kotani, Kaori Yoshida, Tomohisa Iwasaki, Fumihiro Takahashi, Kazuoki Kondo & Hiide Yoshino. (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 16:7, pages 505-512.
Crossref
Crossref
Dmitry Petrov, Colin Mansfield, Alain Moussy & Olivier Hermine. (2017) ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Yorihiro Yamamoto. (2017) Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. Journal of Clinical Biochemistry and Nutrition 60:1, pages 49-54.
Crossref
Crossref
Ting Ju, Xiaoran Wang, Shanshan Zhou, Tingting Zhao, Meimei Yang, Jinghan Lin, Lina Sun, Tingjiao Liu, Yi Xu & Liming Zhang. (2016) Streptozotocin inhibits synaptic transmission and edaravone attenuates streptozotocin-induced electrophysiological changes in CA1 pyramidal neurons of rat hippocampal slices. NeuroToxicology 57, pages 75-86.
Crossref
Crossref
William DeCoteau, Karin L. Heckman, Ana Y. Estevez, Kenneth J. Reed, Wendi Costanzo, David Sandford, Paige Studlack, Jennifer Clauss, Elizabeth Nichols, Jennifer Lipps, Matthew Parker, Bonnie Hays-Erlichman, J.C. Leiter & Joseph S. Erlichman. (2016) Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis. Nanomedicine: Nanotechnology, Biology and Medicine 12:8, pages 2311-2320.
Crossref
Crossref
Tominari Choshi, Haruto Fujioka, Yuhzo Hieda, Noriyuki Hatae, Makoto Anraku, Nobuyasu Matsuura, Kazuhide Uemura, Satoshi Hibino, Hisao Tomida & Osamu Hori. (2016) Antioxidant Effects of the Hydroxy Groups in the Simple Phenolic Carbazoles. HETEROCYCLES 92:1, pages 120.
Crossref
Crossref
Wouter Hubens & Ayako Okado-Matsumoto. 2016. Redox-Active Therapeutics. Redox-Active Therapeutics
605
626
.
Jose Enrique Yuste, Ernesto Tarragon, Carmen María Campuzano & Francisco Ros-Bernal. (2015) Implications of glial nitric oxide in neurodegenerative diseases. Frontiers in Cellular Neuroscience 9.
Crossref
Crossref
Dao-quan Tang, Yin-jie Li, Zheng Li, Ting-ting Bian, Kai Chen, Xiao-xiao Zheng, Yan-yan Yu & Shui-shi Jiang. (2015) Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique. Biomedical Chromatography 29:8, pages 1137-1145.
Crossref
Crossref
Nam-Hee KimMin Oh Lee. (2015) Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis. Korean Journal of Clinical Neurophysiology 17:1, pages 1.
Crossref
Crossref
Yamei Tang, Xiaoming Rong, Weihan Hu, Guoqian Li, Xiaoxia Yang, Jianhua Yang, Pengfei Xu & Jinjun Luo. (2014) Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro-Oncology 120:2, pages 441-447.
Crossref
Crossref
Barış Genç & P. Hande Özdinler. (2014) Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discovery Today 19:4, pages 441-449.
Crossref
Crossref
Feng He, Yan-Ping Cao, Feng-Yuan Che, Lian-Hong Yang, Song-Hua Xiao & Jun Liu. (2014)
Inhibitory Effects of Edaravone in
β
-Amyloid-Induced Neurotoxicity in Rats
. BioMed Research International 2014, pages 1-7.
Crossref
Crossref
Hironobu Eguchi, Haruhiko Sakiyama, Daisaku Yoshihara, Noriko Fujiwara & Keiichiro Suzuki. 2014. Systems Biology of Free Radicals and Antioxidants. Systems Biology of Free Radicals and Antioxidants
3967
3985
.
Emanuele D’Amico, Pam Factor-Litvak, Regina M. Santella & Hiroshi Mitsumoto. (2013) Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology and Medicine 65, pages 509-527.
Crossref
Crossref
Daisuke Yasuda, Kyoko Takahashi, Tomoyuki Ohe, Shigeo Nakamura & Tadahiko Mashino. (2013) Antioxidant activities of 5-hydroxyoxindole and its 3-hydroxy-3-phenacyl derivatives: The suppression of lipid peroxidation and intracellular oxidative stress. Bioorganic & Medicinal Chemistry 21:24, pages 7709-7714.
Crossref
Crossref
Shailendra Kapoor. (2013) Neuroprotective effects of edaravone: Recent insights. Journal of the Neurological Sciences 331:1-2, pages 177.
Crossref
Crossref
Grégory Durand. 2013. Molecular Basis of Oxidative Stress. Molecular Basis of Oxidative Stress
377
406
.
Lucie Ayach, Christophe Curti, Marc Montana, Pascale Pisano & Patrice Vanelle. (2013) Actualités dans le traitement étiologique de la sclérose latérale amyotrophique. Therapies 68:2, pages 93-106.
Crossref
Crossref
Matthew Gladman, Merit Cudkowicz & Lorne Zinman. (2012) Enhancing clinical trials in neurodegenerative disorders. Current Opinion in Neurology 25:6, pages 735-742.
Crossref
Crossref
Koji Abe. (2012) Clinical Features, Pathogenesis, and Therapy for ALS. Spinal Surgery 26:3, pages 270-277.
Crossref
Crossref
Paul H. Gordon & Vincent Meininger. (2011) How can we improve clinical trials in amyotrophic lateral sclerosis?. Nature Reviews Neurology 7:11, pages 650-654.
Crossref
Crossref
Masashi Aoki, Hitoshi Warita, Hideki Mizuno, Naoki Suzuki, Satoshi Yuki & Yasuto Itoyama. (2011) Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Research 1382, pages 321-325.
Crossref
Crossref
KIYOSHI KIKUCHI, KO-ICHI KAWAHARA, HISAAKI UCHIKADO, NAOHISA MIYAGI, TERUKAZU KURAMOTO, TOMOYA MIYAGI, YOKO MORIMOTO, TAKASHI ITO, SALUNYA TANCHAROEN, NAOKI MIURA, KAZUNORI TAKENOUCHI, YOKO OYAMA, BINITA SHRESTHA, FUMIYO MATSUDA, YOSHIHIRO YOSHIDA, SHINIHIRO ARIMURA, KENTARO MERA, KO-ICHI TADA, NARIMASA YOSHINAGA, RYUICHI MAENOSONO, YOSHIKO OHNO, TERUTO HASHIGUCHI, IKURO MARUYAMA & MINORU SHIGEMORI. (2011) Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Experimental and Therapeutic Medicine 2:5, pages 771-775.
Crossref
Crossref
Paul H. Gordon. (2011) Amyotrophic Lateral Sclerosis. CNS Drugs 25:1, pages 1-15.
Crossref
Crossref
A. Y. Estevez & J. S. Erlichman. 2011. Oxidative Stress: Diagnostics, Prevention, and Therapy. Oxidative Stress: Diagnostics, Prevention, and Therapy
255
288
.
Yong‐Hui Pan, Yong‐Chen Wang, Li‐Ming Zhang & Shu‐Rong Duan. (2010) Protective effect of edaravone against PrP106‐126–induced PC12 cell death. Journal of Biochemical and Molecular Toxicology 24:4, pages 235-241.
Crossref
Crossref
Jeban Ganesalingam & Robert Bowser. (2010) The application of biomarkers in clinical trials for motor neuron disease. Biomarkers in Medicine 4:2, pages 281-297.
Crossref
Crossref
Chunyan Gao, Xiaorong Li, Yuhang Li, Lijuan Wang & Ming Xue. (2010) Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. Journal of Pharmacy and Pharmacology 62:3, pages 360-367.
Crossref
Crossref
Da-Zhi Liu, Bradley P. Ander & Frank R. Sharp. (2010) Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases. Neurobiology of Disease 37:3, pages 549-557.
Crossref
Crossref
Siân C. Barber & Pamela J. Shaw. (2010) Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radical Biology and Medicine 48:5, pages 629-641.
Crossref
Crossref
Barrie J. CarterPervin AnklesariaStephanie ChoiJohn F. Engelhardt. (2009) Redox Modifier Genes and Pathways in Amyotrophic Lateral Sclerosis. Antioxidants & Redox Signaling 11:7, pages 1569-1586.
Crossref
Crossref
Ryosuke Takahashi. (2009) Edaravone in ALS. Experimental Neurology 217:2, pages 235-236.
Crossref
Crossref
Richard S. Bedlack & Swati Aggarwal. (2009) ALS UPDATE. CONTINUUM: Lifelong Learning in Neurology 15, pages 83-110.
Crossref
Crossref
Masaharu Hayashi. (2009) Oxidative stress in developmental brain disorders. Neuropathology 29:1, pages 1-8.
Crossref
Crossref
Jinsy Andrews. (2008) Amyotrophic lateral sclerosis: Clinical management and research update. Current Neurology and Neuroscience Reports 9:1, pages 59-68.
Crossref
Crossref
Benjamin Rix Brooks. (2009) Managing amyotrophic lateral sclerosis: Slowing disease progression and improving patient quality of life. Annals of Neurology 65:S1, pages S17-S23.
Crossref
Crossref
Hidefumi Ito, Reika Wate, Jianhua Zhang, Shizuo Ohnishi, Satoshi Kaneko, Hisashi Ito, Satoshi Nakano & Hirofumi Kusaka. (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Experimental Neurology 213:2, pages 448-455.
Crossref
Crossref
B. Jane Distad, Gregg D. Meekins, Lee L. Liou, Michael D. Weiss, Gregory T. Carter & Robert G. Miller. (2008) Drug Therapy in Amyotrophic Lateral Sclerosis. Physical Medicine and Rehabilitation Clinics of North America 19:3, pages 633-651.
Crossref
Crossref
Mauro CozzolinoAlberto FerriMaria Teresa Carrì. (2008) Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications. Antioxidants & Redox Signaling 10:3, pages 405-444.
Crossref
Crossref